Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

Bioengineered ankyrin compounds show high in vitro activity against SARS-CoV-2 mutants

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

SARS-CoV-2 escape mutations identified against monoclonal antibodies and polyclonal immune sera

COVID-19 pandemic and nanotechnology

COVID-19 pandemic and nanotechnology

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

Study finds protective genetic associations with mild COVID-19

Study finds protective genetic associations with mild COVID-19

Variants emerging during COVID-19 pandemic resist antibody neutralization

Variants emerging during COVID-19 pandemic resist antibody neutralization

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

New data on impact of spike mutations and B117 UK variant on neutralization by mAbs and sera

New data on impact of spike mutations and B117 UK variant on neutralization by mAbs and sera

Dynamic, customized treatment approaches for gastroesophageal cancers may improve survival rates

Dynamic, customized treatment approaches for gastroesophageal cancers may improve survival rates

Patients fend for themselves to access highly touted covid antibody treatments

Patients fend for themselves to access highly touted covid antibody treatments

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Immune systems of COVID-19 patients may rely on antibodies from earlier coronaviruses

Immune systems of COVID-19 patients may rely on antibodies from earlier coronaviruses

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.